Specificity of human anti‐variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor‐α receptor 1

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2249|182|2|139-148

ISSN： 0009-9104

Source： CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol.182, Iss.2, 2015-11, pp. : 139-148

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long persistence of tumour necrosis factor‐α antagonist‐induced autoantibodies under subsequent treatment with ustekinumab but no adverse effects: a case study of 14 patients with psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : e9-e10

John Wiley & Sons Inc

Access to resources Recommend Favorite

Resistance to Human Cytomegalovirus Infection may be Influenced by Genetic Polymorphisms of the Tumour Necrosis Factor-alpha and Interleukin-1 Receptor Antagonist Genes

By Hurme Mikko   Helminen Merja  

Scandinavian Journal of Infectious Diseases, Vol. 30, Iss. 5, 1998-12 ,pp. : 447-449

Informa Healthcare

Access to resources Recommend Favorite

Epitope Specificity Determines Pathogenicity and Detectability of Anti–Platelet‐Derived Growth Factor Receptor α Autoantibodies in Systemic Sclerosis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 7, 2015-07 ,pp. : 1891-1903

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tumour necrosis factor‐α antagonists as therapies for vitiligo

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 3, 2015-09 ,pp. : 635-635

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tumour necrosis factor‐α antagonists as therapies for vitiligo

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 7-0963, Iss. 3, 2015-09 ,pp. : 635-635

John Wiley & Sons Inc

Access to resources Recommend Favorite